Abstract: Desmycinosyl derivatives of 12,13-desepoxy-12,13-dehydro antibiotic AR-5 component 1 and 12,13-desepoxy-12,13-dehydro antibiotic AR-5 component 2 are useful antibacterial agents and may be converted to other such agents by processes analogous to those generally known in the art.

Abstract: Novel macrolide antibacterial derivatives of the components of the Antibiotic AR-5-complex are disclosed herein. The invention specifically relates to compounds wherein the macrolide ring and/or the two attached sugars are derivatized. Also disclosed are methods for the preparation of the derivatives and methods for the use thereof.

Abstract: 6-(Heterocyclic)hydroxymethylpenicillanic acids and compounds related thereto are prepared by reaction of a 6,6-dihalopenicillanic acid with a Grignard reagent and a heterocyclic aldehyde in an anhydrous aprotic solvent. The compounds possess useful antibacterial activity.

Abstract: .beta.-Lactams having a substituted hydroxymethylene group at the position .alpha. to the lactam carbonyl group are prepared by reaction of an .alpha.-halo-.beta.-lactam with zinc or zinc amalgam in an anhydrous aprotic medium to produce an intermediate which in situ reacts with an appropriate aldehyde or ketone.Also described are novel penicillins and cephalosporins having useful antibacterial activity.

Abstract: Rosaramicin and 12,13-desepoxy-12,13-dehydrorosaramicin form novel 20-imino-20-deoxy derivatives having substantial antibacterial activity. Methods for preparing such compounds are also disclosed.

Abstract: .beta.-Lactams having a substituted hydroxymethylene group at the position .alpha. to the lactam carbonyl group are prepared by reaction of an .alpha.-halo-.beta.-lactam with zinc or zinc amalgam in an anhydrous aprotic medium to produce an intermediate which in situ reacts with an appropriate aldehyde or ketone.Also described are noval penicillins and cephalosporins having useful antibacterial activity.

Abstract: Everninomicin B, C or D may be converted to amino derivatives by reductive means. The amino derivatives may, subsequently, be converted to novel N-acyl, N-alkyl or N,N-dialkyl derivatives. Alternatively, everninomicins B, C or D may be converted to N-acyl-N-hydroxylamino derivatives also by reductive means. The derivatives so-produced and the non-toxic pharmaceutically acceptable cationic salts thereof are novel and are antibacterial agents.

Abstract: This disclosure relates to the method for the treatment of psoriasis which comprises the topical administration to a mammal suffering from psoriasis of an effective dose for treating psoriasis of a 7X-5Q-3Y-3H-.gamma.-triazolo[4,5-d]-pyrimidine wherein X is halogeno, alkoxy, or --NRR.sub.1, R and R.sub.1 being lower alkyl, Y is cycloalkyl, hydroxycycloalkyl, phenyl, bicycloalkyl, or A--R.sub.2 with A being methylene or ethylene and R.sub.2 being phenyl or bicycloalkyl, and Q is hydrogen or Y.

Abstract: Everninomicin derivatives devoid of a nitro group and having antibacterial activity are prepared by electrochemically reducing the corresponding everninomicin having a nitro function or salts thereof in an aprotic anhydrous solvent in the absence of carbon dioxide. A preferred starting compound is everninomicin D whereby is produced a product mixture of antibacterial agents identified as desevernitrose everninomicin D, everninomicin D-3, and everninomicin D-7, respectively.

Abstract: Everninomicin antibiotics having a nitro function, e.g. everninomicin B, everninomicin C, and everninomicin D, upon treatment with aluminum amalgam in aqueous alkanol are converted to a mixture of at least two reduction products having antibacterial activity, said reduction products being an everninomicin having a nitroso function and an everninomicin having a hydroxylamino function. The nitrosoeverninomicins are also prepared by treating the corresponding hydroxylaminoeverninomicin with an oxidizing reagent selected from the group consisting of aerial oxidation in alkaline solution, and an alkali metal hypobromite in an aprotic solvent. The everninomicin reduction products and salts thereof are described as well as nitrone derivatives of the hydroxylaminoeverninomicins and salts thereof, all of which possess antibacterial activity. A preferred compound is hydroxylaminoeverninomicin D, particularly the sodium salt thereof.

Abstract: Hydroxylaminoeverninomicins having antibacterial activity are prepared by electrochemically reducing the corresponding everninomicin having a nitro function or the corresponding nitrosoeverninomicin in an aqueous miscible organic solvent under an inert atmosphere or in an anhydrous aprotic solvent in the presence of carbon dioxide. Additionally, nitrosoeverninomicins, upon electrochemical reduction in an aprotic solvent under an inert atmosphere, are converted to the corresponding hydroxylaminoeverninomicins. Preferred starting compounds are everninomicins B, C and D whereby are obtained hydroxylaminoeverninomicins B, C and D, respectively. Particularly useful is the electrochemical reduction of everninomicin D in anhydrous dimethylformamide in the presence of carbon dioxide to obtain hydroxylaminoeverninomicin D of excellent purity in high yields.

Abstract: Described is a novel process for the preparation of 12,13-desepoxy-12,13-dehydrorosamicin by reducing rosamicin in a mineral acid solution containing Cr.sup.+.sup.+ cations. Rosamicin is an antibiotic elaborated by Micromonospora rosaria.